Evidence map›Paper›PMID 42132187›Full record

ReviewInternational journal of immunogenetics2026

Recommendations From the Implementation Steering Group for Organ Utilisation Histocompatibility and Immunogenetics Sub-Group: ISOU H&I Sub-Group Recommendations.

Nicola C Speirs, Victoria Chalker, Brendan Clark, Aisling E Courtney, Sunil Daga, Sian Griffin, Delordson Kallon, Jon Jin Kim, Vasilis Kosmoliaptsis, Katy Latham and 5 more

Abstract readReview
In one paragraph

Review in International journal of immunogenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nicola C SpeirsH&I Laboratory, SNBTS, Edinburgh Royal Infirmary, NHS National Services Scotland, Edinburgh, UK.
Victoria ChalkerNHS England, London, UK.
Brendan ClarkLeeds Teaching Hospitals NHS Trust, Leeds, UK.
Aisling E CourtneyRegional Nephrology & Transplant Unit, Belfast City Hospital, Belfast, UK.
Sunil DagaLeeds Teaching Hospitals NHS Trust, Leeds, UK.
Sian GriffinCardiff and Vale University Health Board, Cardiff, UK.
Delordson KallonClinical Transplantation Laboratory, NHS East and South East London Pathology Partnership, Barts Health NHS Trust, London, UK.
Jon Jin KimDepartment of Surgery, University of Cambridge, Cambridge, UK.
Vasilis KosmoliaptsisDepartment of Surgery, University of Cambridge, Cambridge, UK.
Katy LathamNHS Blood and Transplant, London, UK.
Sarah PeacockCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Olivia ShawClinical Transplantation Laboratory, Guys Hospital, Synnovis, London, UK.
Thomas NietoDepartment of Renal Transplant Surgery, Queen Elizabeth Hospital, Birmingham, UK.
Rommel RavananNorth Bristol NHS Trust, Bristol, UK.
Richard BattleH&I Laboratory, SNBTS, Edinburgh Royal Infirmary, NHS National Services Scotland, Edinburgh, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Organ Utilisation Group was established to address barriers in solid organ transplantation and improve patient outcomes across the United Kingdom. The group produced a series of recommendations in February 2023. To address these recommendations, the Department of Health and Social Care formed the Implementation Steering Group for Organ Utilisation (ISOU). A dedicated Histocompatibility and Immunogenetics (H&I) sub-group was formed with a remit to provide recommendations for HLA compatibility assessments and new technologies that could improve patient outcomes, within a 5 to 10 year time frame. The ISOU H&I sub-group made five key recommendations, grouped under three themes: (1) implementation and digital capture of high-resolution HLA typing data for organ donor and recipients; (2) utilising high-resolution HLA typing data to improve donor/recipient compatibility assessment and patient outcomes and (3) use of other technologies/innovations to improve patient outcomes. This article discusses the recommendations with an emphasis on advanced technologies and methodologies such as high-resolution HLA typing, molecular matching, non-HLA antigen systems, donor-derived cell-free DNA (dd-cfDNA) and artificial intelligence (AI). Implementation of these recommendations aims to enhance organ matching, reduce immunological risk and improve equity and long-term outcomes for transplant recipients and position UK transplantation services at the forefront of innovation and patient-centred care.

Indexed as

HistocompatibilityHistocompatibility TestingHLA AntigensImmunogeneticsOrgan TransplantationTissue and Organ ProcurementHumansTissue DonorsUnited KingdomHLA Antigensdd‐cfDNAHLAISOUrecommendations

Identifiers

PMID42132187
PMCPMC13352101

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.